
Rivia is a unified data and AI analytics platform designed for biotech and pharmaceutical companies to optimize clinical trials. It integrates fragmented trial data from multiple vendor sources into a standardized relational database using an AI Data Integration Engine, delivering real-time, clean, and consistent data for actionable insights. The platform includes Rivia Spark, an AI-powered visual intelligence tool that transforms natural language queries into dynamic visualizations and patient-specific insights. Rivia's solutions enhance decision-making across medical and clinical science, safety monitoring, clinical operations, and executive oversight, reducing risks, costs, and accelerating time to market. Trusted by leading innovators like Alentis Therapeutics, Calypso Biotech, and Abcentra Therapeutics, Rivia positions itself as a leader in transforming clinical trial data into insights that drive therapeutic innovation globally.

Rivia is a unified data and AI analytics platform designed for biotech and pharmaceutical companies to optimize clinical trials. It integrates fragmented trial data from multiple vendor sources into a standardized relational database using an AI Data Integration Engine, delivering real-time, clean, and consistent data for actionable insights. The platform includes Rivia Spark, an AI-powered visual intelligence tool that transforms natural language queries into dynamic visualizations and patient-specific insights. Rivia's solutions enhance decision-making across medical and clinical science, safety monitoring, clinical operations, and executive oversight, reducing risks, costs, and accelerating time to market. Trusted by leading innovators like Alentis Therapeutics, Calypso Biotech, and Abcentra Therapeutics, Rivia positions itself as a leader in transforming clinical trial data into insights that drive therapeutic innovation globally.
Company: Rivia — unified data & AI analytics platform for clinical trials
Headquarters: Zurich, Switzerland
Founded: 2022
Core product: Rivia Core (AI data-integration) and Rivia Spark (AI visual analytics)
Recent funding: Seed round announced Jun 12, 2024 (lead: Speedinvest)
Clinical trial data fragmentation and slow, inconsistent analytics across vendors and data sources.
2022
Software Development
Seed round announced Jun 12, 2024; press coverage reported approximately €3M
Single non-equity assistance round recorded with three investors
“Backed by early-stage investors including Speedinvest, Nina Capital, and Amino Collective”
| Company |
|---|